Cite
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
MLA
Joseph Han, et al. “Adjuvant NY-ESO-1 Vaccine Immunotherapy in High-Risk Resected Melanoma: A Retrospective Cohort Analysis.” Journal for Immunotherapy of Cancer, vol. 6, no. 1, Dec. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d622ce36ba867fe972b73a8708d05482&authtype=sso&custid=ns315887.
APA
Joseph Han, Kierstin Utter, Anna C. Pavlick, Michael Lattanzi, Jeremy Tchack, Rachel Lubong Sabado, Nina Bhardwaj, Iman Osman, Una Moran, Russell S. Berman, Richard L. Shapiro, & Hsin-Hui Huang. (2017). Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for Immunotherapy of Cancer, 6(1).
Chicago
Joseph Han, Kierstin Utter, Anna C. Pavlick, Michael Lattanzi, Jeremy Tchack, Rachel Lubong Sabado, Nina Bhardwaj, et al. 2017. “Adjuvant NY-ESO-1 Vaccine Immunotherapy in High-Risk Resected Melanoma: A Retrospective Cohort Analysis.” Journal for Immunotherapy of Cancer 6 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d622ce36ba867fe972b73a8708d05482&authtype=sso&custid=ns315887.